Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Folotyn (pralatrexate) is a folate analog metabolic inhibitor used to treat peripheral T-cell lymphoma, a rare and aggressive form of non-Hodgkin lymphoma.
Folotyn is FDA-approved for adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
Pralatrexate competitively inhibits dihydrofolate reductase and disrupts folate-dependent metabolic processes required for DNA synthesis, preferentially affecting rapidly dividing cancer cells.
The recommended dose is 30 mg/m² administered by intravenous push over 3 to 5 minutes, once weekly for 6 weeks in 7-week cycles, until disease progression or unacceptable toxicity. Patients also receive vitamin B12 injections and daily folic acid supplementation to reduce toxicity, as directed by the treating hematologist-oncologist.
Folotyn carries several important safety considerations that require close monitoring.
Monitor for mucositis weekly. Omit or reduce the dose for Grade 2 or higher mucositis.
Thrombocytopenia, neutropenia, and anemia can occur. Vitamin B12 and folic acid supplementation are required throughout treatment to help reduce this risk. Monitor blood counts regularly.
Severe and sometimes fatal skin reactions have been reported, including skin exfoliation, ulceration, and toxic epidermal necrolysis. Monitor closely for any new or worsening skin symptoms and discontinue promptly if severe reactions occur.
Monitor patients with high tumor burden for signs of tumor lysis syndrome.
Folotyn can cause fetal harm. Effective contraception is required during treatment and for a defined period after the final dose.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Folotyn (pralatrexate) received FDA approval in 2009 and is currently manufactured by Acrotech Biopharma for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Import of Folotyn through a Named Patient Program requires a valid prescription from the treating hematologist-oncologist, confirmation of PTCL diagnosis and treatment history, and supporting clinical documentation as required by Indian regulatory authorities.
NPP sources Folotyn directly from Acrotech Biopharma's authorized supply chain to ensure product authenticity and regulatory compliance.
Folotyn is sourced through verified, GDP-compliant, cold-chain channels from Acrotech Biopharma's authorized supply chain to ensure authenticity and quality.
Folotyn should be stored refrigerated at 2°C to 8°C, in the original carton to protect from light.
Once sourced, Folotyn is packed and transported under continuous cold-chain conditions to preserve product integrity throughout the import process, with tracking and updates provided at each stage of delivery to the patient or treating hospital in India.
Patients across India can access Folotyn through NPP's regulated import pathway, with hematology-oncology specialists in major cities supporting the treatment process.
Leading hematology-oncology centers in Mumbai support PTCL diagnosis and treatment coordination for Folotyn access.
Delhi's major cancer hospitals assist patients with diagnostic confirmation and prescription support for Folotyn.
Bangalore's oncology network offers access to lymphoma treatment planning for eligible patients.
Chennai-based specialists coordinate Folotyn access alongside comprehensive lymphoma care.
Hyderabad's cancer care institutions support patients pursuing Folotyn therapy.
Kolkata's oncology centers help coordinate documentation and treatment access for Folotyn.
Pune-based hematologists assist with diagnosis confirmation and Folotyn treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Folotyn.
Kochi's oncology units assist patients with the documentation needed for Folotyn access.
Chandigarh's cancer care centers support Folotyn treatment coordination for patients from North India.
Jaipur's oncology specialists help patients navigate the Folotyn access process.
Lucknow-based cancer centers assist patients pursuing Folotyn therapy.
Bhubaneswar's oncology institutions support access to Folotyn for eligible patients.
Guwahati's specialists help coordinate Folotyn access for patients across the Northeast.
Patients in other cities across India can also access Folotyn through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 10 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 10 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
